Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends

Figure 1 Natural history and pathogenesis of metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis. The metabolic dysfunction-associated steatotic liver disease spectrum extends from simple steatosis to steatohepatitis to fibrosis and cirrhosis and could predispose to hepatocellular carcinoma. The "multiple hit" hypothesis best explains the pathogenesis, although the sequence or influence of each hit is unclear and may vary between individual patients.